Adoram Therapeutics
Adoram develops novel small molecule immunotherapies by leveraging allosteric biochemistry to treat solid tumors and immune-based diseases. The company focuses on creating best-in-class treatments, such as an A2AR NAM, that offer improved potency and safety over existing approaches. Their technology platform also screens for other GPCR drug targets to expand their pipeline for unmet medical needs.
- Biotechnology
Updated 11 months ago
Funding
Raised to date
$1.1MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
across 1 round
I
$1.1M · Grant
Announced May 2025
Disclosed cumulative: $1.1M
RoundDateAmountValuationInvestors
Founders
Product
Features
- Adoram develops novel small molecule immunotherapies by leveraging allosteric biochemistry to treat solid tumors and immune-based diseases. The company focuses on creating best-in-class treatments, such as an A2AR NAM, that offer improved potency and safety over existing approaches. Their technology platform also screens for other GPCR drug targets to expand their pipeline for unmet medical needs.